Pfizer eyes $26B in COVID-19 vaccine sales for the year, with $3.5B already in the bag

In the first three months of 2021, Pfizer's COVID-19 vaccine pulled in as much revenue as some pharma blockbusters make in an entire year. That’s just the beginning, as Pfizer eyes sales from more than a billion additional doses before the end of 2021.